Phase II trial of pirfenidone in adults with neurofibromatosis type 1
- 28 November 2006
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 67 (10) , 1860-1862
Abstract
We performed an open-label phase II trial of oral pirfenidone in 24 patients with neurofibromatosis type 1 (NF1). Tumors were monitored by three-dimensional MRI. At the end of treatment, four patients had a decrease in tumor volume by 15% or more, three had tumor progression, and 17 remained stable. Pirfenidone warrants further investigation in NF1, which has until now lacked an effective control therapy.Keywords
This publication has 6 references indexed in Scilit:
- Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imagingComputerized Medical Imaging and Graphics, 2004
- Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1Neurology, 2003
- Review ArticLe : Therapy for Plexiform Neurofibromas in Children With Neurofibromatosis 1: An OverviewJournal of Child Neurology, 2002
- Plexiform neurofibromasAmerican Journal of Medical Genetics, 1999
- Prognostic signs in the surgical management of plexiform neurofibroma: The Children’s Hospital of Philadelphia experience, 1974-1994The Journal of Pediatrics, 1997
- Magnetic resonance image–based hippocampal volumentry: Correlation with outcome after temporal lobectomyAnnals of Neurology, 1992